CR10870A - PURINE DERIVATIVES 7-REPLACED FOR IMMUNOSUPPRESSION - Google Patents

PURINE DERIVATIVES 7-REPLACED FOR IMMUNOSUPPRESSION

Info

Publication number
CR10870A
CR10870A CR10870A CR10870A CR10870A CR 10870 A CR10870 A CR 10870A CR 10870 A CR10870 A CR 10870A CR 10870 A CR10870 A CR 10870A CR 10870 A CR10870 A CR 10870A
Authority
CR
Costa Rica
Prior art keywords
immunosuppression
replaced
purine derivatives
derivatives
moderate
Prior art date
Application number
CR10870A
Other languages
Spanish (es)
Inventor
Michael Ohlmeyer
Adolph Bohnstedt
Celia Kingsbury
Koc-Kan Ho
Jorge Quintero
Original Assignee
Pharmacopeia Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacopeia Llc filed Critical Pharmacopeia Llc
Publication of CR10870A publication Critical patent/CR10870A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invencion provee nuevos derivados de purinona y derivados relacionados utiles para la prevencion y tratamiento de enfermedades autoinmunes, enfermedad inflamatoria, enfermedad moderada por celula cebada y rechazo de trasplante. Los compuestos de la formula general (III).The present invention provides new purinone derivatives and related derivatives useful for the prevention and treatment of autoimmune diseases, inflammatory disease, moderate barley cell disease and transplant rejection. The compounds of the general formula (III).

CR10870A 2006-11-16 2009-06-16 PURINE DERIVATIVES 7-REPLACED FOR IMMUNOSUPPRESSION CR10870A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2006/061004 WO2008060301A1 (en) 2006-11-16 2006-11-16 7-substituted purine derivatives for immunosuppression

Publications (1)

Publication Number Publication Date
CR10870A true CR10870A (en) 2009-12-01

Family

ID=38578618

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10870A CR10870A (en) 2006-11-16 2009-06-16 PURINE DERIVATIVES 7-REPLACED FOR IMMUNOSUPPRESSION

Country Status (11)

Country Link
EP (1) EP2099800A1 (en)
JP (1) JP2010510211A (en)
KR (1) KR20100014271A (en)
CN (1) CN101595110A (en)
AU (1) AU2006350748A1 (en)
BR (1) BRPI0622030A2 (en)
CA (1) CA2669686A1 (en)
CR (1) CR10870A (en)
IL (1) IL198761A0 (en)
MX (1) MX2009005194A (en)
WO (1) WO2008060301A1 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7884109B2 (en) * 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US7989459B2 (en) * 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
ES2543216T3 (en) 2009-03-13 2015-08-17 Katholieke Universiteit Leuven, K.U. Leuven R&D Thiazolopyrimidine modulators as immunosuppressive agents
WO2010118986A1 (en) 2009-04-14 2010-10-21 Cellzome Limited Fluoro substituted pyrimidine compounds as jak3 inhibitors
CA2771675A1 (en) 2009-09-11 2011-03-17 Cellzome Limited Ortho substituted pyrimidine compounds as jak inhibitors
BR112012009327A2 (en) 2009-10-20 2017-06-06 Cellzome Ltd pyrazolopyrimidine heterocyclyl analogs as jak inhibitors
UA109775C2 (en) 2009-10-29 2015-10-12 N-containing heteroaryl derivatives as JAK3 kinase inhibitors
KR20130094693A (en) 2010-04-30 2013-08-26 셀좀 리미티드 Pyrazole compounds as jak inhibitors
GB201012889D0 (en) 2010-08-02 2010-09-15 Univ Leuven Kath Antiviral activity of novel bicyclic heterocycles
MY189483A (en) 2010-05-31 2022-02-16 Ono Pharmaceutical Co Purinone derivative
WO2012003576A1 (en) * 2010-07-06 2012-01-12 Université de Montréal Imidazopyridine, imidazopyrimidine and imidazopyrazine derivatives as melanocortin-4 receptor modulators
JP2013534233A (en) 2010-08-20 2013-09-02 セルゾーム リミティッド Heterocyclylpyrazolopyrimidine analogs as selective JAK inhibitors
KR101227388B1 (en) * 2010-09-09 2013-01-30 주식회사 만도 3 way type lp egr valve constitution
GB201015411D0 (en) 2010-09-15 2010-10-27 Univ Leuven Kath Anti-cancer activity of novel bicyclic heterocycles
CA2825098C (en) 2011-01-27 2020-03-10 Universite De Montreal Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
WO2012143320A1 (en) 2011-04-18 2012-10-26 Cellzome Limited (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors
JP2014521623A (en) 2011-07-28 2014-08-28 セルゾーム リミティッド Heterocyclyl pyrimidine analogs as JAK inhibitors
WO2013017479A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
WO2013017480A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
WO2013025628A1 (en) 2011-08-15 2013-02-21 Ligand Pharmaceuticals Incorporated Janus kinase inhibitor compounds and methods
RU2014115476A (en) 2011-09-20 2015-10-27 Целльзом Лимитед PYRAZOLO [4, 3-C] PTRIDINE DERIVATIVES AS KINASE INHIBITORS
MX353548B (en) 2011-11-29 2018-01-18 Ono Pharmaceutical Co Purinone derivative hydrochloride.
WO2013092854A1 (en) 2011-12-23 2013-06-27 Cellzome Limited Pyrimidine-2,4-diamine derivatives as kinase inhibitors
US8501724B1 (en) * 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
WO2014013014A1 (en) 2012-07-18 2014-01-23 Fundació Privada Centre De Regulació Genòmica (Crg) Jak inhibitors for activation of epidermal stem cell populations
WO2015089218A1 (en) 2013-12-10 2015-06-18 David Wustrow Monocyclic pyrimidine/pyridine compounds as inhibitors of p97 complex
ES2819867T3 (en) 2014-01-20 2021-04-19 Cleave Biosciences Inc Condensed pyrimidines as inhibitors of the p97 complex
US9416131B2 (en) 2014-03-25 2016-08-16 Ono Pharmaceutical Co., Ltd. Prophylactic agent and/or therapeutic agent for diffuse large B-cell lymphoma
US10239879B2 (en) 2015-04-09 2019-03-26 Ono Pharmaceutical Co., Ltd. Process for producing purinone derivative
CA3005353A1 (en) 2015-11-20 2017-05-26 Forma Therapeutics, Inc. Purinones as ubiquitin-specific protease 1 inhibitors
WO2018041989A1 (en) 2016-09-02 2018-03-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating refractory celiac disease type 2
CN110621652A (en) * 2017-05-17 2019-12-27 株式会社德山 Process for producing diaminobenzene compound
JP2022527972A (en) 2019-04-02 2022-06-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル How to predict and prevent cancer in patients with premalignant lesions
US20220202820A1 (en) 2019-04-16 2022-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels
KR102516260B1 (en) * 2020-07-10 2023-03-31 울산과학기술원 Compounds as a TRAP1 selective inhibitor, and composition for preventing or treating cancer comprising the same
KR102579424B1 (en) * 2021-02-19 2023-09-18 울산과학기술원 Compounds as a TRAP1 selective inhibitor with increased mitochondrial drug accumulation, and use thereof
WO2023222565A1 (en) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100465173C (en) * 2004-01-12 2009-03-04 西托匹亚研究有限公司 Selective kinase inhibitors
AR054416A1 (en) * 2004-12-22 2007-06-27 Incyte Corp PIRROLO [2,3-B] PIRIDIN-4-IL-AMINAS AND PIRROLO [2,3-B] PIRIMIDIN-4-IL-AMINAS AS INHIBITORS OF THE JANUS KINASES. PHARMACEUTICAL COMPOSITIONS.
MX2007009429A (en) * 2005-02-03 2008-03-18 Vertex Pharma Pyrrolopyrimidines useful as inhibitors of protein kinase.
WO2006108103A1 (en) * 2005-04-05 2006-10-12 Pharmacopeia, Inc. Purine and imidazopyridine derivatives for immunosuppression

Also Published As

Publication number Publication date
KR20100014271A (en) 2010-02-10
CN101595110A (en) 2009-12-02
EP2099800A1 (en) 2009-09-16
WO2008060301A1 (en) 2008-05-22
BRPI0622030A2 (en) 2014-04-22
AU2006350748A1 (en) 2008-05-22
JP2010510211A (en) 2010-04-02
AU2006350748A2 (en) 2009-08-06
CA2669686A1 (en) 2008-05-22
MX2009005194A (en) 2009-11-10
IL198761A0 (en) 2010-02-17

Similar Documents

Publication Publication Date Title
CR10870A (en) PURINE DERIVATIVES 7-REPLACED FOR IMMUNOSUPPRESSION
AR063141A1 (en) DERIVATIVES OF 2- (BENZIMIDAZOLIL) PURINA 8- REPLACED FOR IMMUNOSUPPRESSION
CL2011002956A1 (en) Compounds derived from pyrrolo [2,3-d] pyrimidine, inhibitors of janus kinase (jak1); pharmaceutical composition; and use for the treatment of an autoimmune disease, cancer, myeloproliferative disorder, an inflammatory disease, or organ transplant rejection.
ECSP109937A (en) PYRIMIDIL CYCLOPENTANS AS INHIBITORS OF THE PROTEIN QUINASA AKT.
UY29149A1 (en) TIAZOLIL-DIHIDRO-INDAZOLES
CR9840A (en) PDE INHIBITORS AND COMBINATIONS OF THE SAME FOR THE TREATMENT OF UROLOGICAL DISORDERS
CR11517A (en) BIS- (SULFONYLAMINE) DERIVATIVES FOR USE IN THERAPY
ECSP078013A (en) MEK HETEROCYCLIC INHIBITORS AND METHODS OF USE OF THEM
ECSP11011284A (en) Poly (ADP-ribose) Polymerase (PARP) inhibitors
CR10601A (en) CYCLOPENTA (D) PYRIMIDINS AS INHIBITORS OF THE PROTEIN CINASA AKT
DOP2006000169A (en) BETA-SECRETASE SPIROPIPERIDINE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
NO20075560L (en) Purine and imidazopyridine derivatives for immunosuppression
DOP2010000217A (en) 3H- [1,2,3] TRIAZOLO [4,5-D] PIRIMIDINE COMPOUNDS, THEIR USE AS INHIBITORS OF MOTOR KINASE AND P13 AND THEIR SYNTHESIS
ECSP099044A (en) FUSIONED PYRIMID COMPOUNDS
GT200600035A (en) AMINOPIRIDINS AS INHIBITORS OF BETA-SECRETASA
UY29826A1 (en) PIRIMIDINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS OF THE SAME HYDROLYSABLES IN VIVO, PREPARATION PROCESSES AND APPLICATIONS
ECSP077268A (en) RAPAMYCIN POLYMORPH II AND THE USES OF THE SAME
CL2008001659A1 (en) Quinoxaline derived compounds as inhibitors of the tyrosine kinase activity of janus kinases; pharmaceutical composition comprising said compounds; and its use to treat an immunological disease selected from organ transplant rejection, lupus, multiple sclerosis, among other diseases.
TW200631583A (en) Substituted pteridines for the treatment of inflammatory diseases
CL2011001360A1 (en) Compounds derived from imidazol [1,2-a] pyrazin-8-amine, splenic tyrosine kinase inhibitors; pharmaceutical composition comprising a compound; use of the compounds in the preparation of medicaments for the treatment of allergic disorders, autoimmune diseases and inflammatory diseases; and in vitro method.
CU20120059A7 (en) PIRROLO COMPOUNDS [2,3-D] PYRIMIDINE
CL2012000917A1 (en) Compounds derived from pyrazolo [3,4-d] pyrimidine, btk inhibitors; and use in the treatment of cancer, autoimmune diseases, mastocytosis, osteoporosis, among others.
WO2009024542A3 (en) Purin derivatives for use in the treatment of fab-related diseases
RU2711869C3 (en) Imidazopyrrolopyrazine derivatives useful in the treatment of diseases caused by abnormal activity of Jak1, Jak3 or Syk protein kinases
ITTO20050719A1 (en) STRUCTURE OF REAR LIGHT FOR VEHICLES.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)